Abstract
The evaluation of Helicobacter pylori infection or the presence of chronic gastritis induced by H. pylori is regarded as the most important risk factor for gastric cancer development. The serum antibody test against H. pylori is the most popular in the clinical practice as well as for a population-based gastric cancer mass survey. However, some H. pylori-infected patients had negative titer (called negative-high titer), which may be induced by unexpected or accidental eradication of H. pylori. Serum pepsinogen (PG) is another popular serum marker for evaluating the status of gastric inflammation. Miki first established a systematic diagnostic panel with PG-I and PG I/II levels to evaluate gastric cancer risk, which was called the “pepsinogen test.” Further, Miki and Inoue created a diagnostic panel by combination of serum anti-H. pylori antibody titer and the PG test, which is called the “ABC risk stratification system.” However, in this system, contamination of patients with past infection of H. pylori into Group A is a crucial problem called the “pseudo A problem.” Recently, the Japanese Society for Helicobacter Research have created a new flow chart for diagnosis and treatment by considering gastric cancer risk by H. pylori infection. In this panel, morphological (endoscopic) evaluation is included to diagnose H. pylori-uninfected patients with serum antibody test.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
IARC Working Group Reports Vol. 8. Helicobacter pylori eradication as a strategy for preventing gastric cancer.
Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
Kawai T, Kawakami K, Kudo T, et al. A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med. 2002;41(10):780–3.
Kotachi T, Ito M, Yoshihara M, et al. Serological evaluation of gastric cancer risk by pepsinogen and Helicobacter pylori antibody; relationship to endoscopic findings. Digestion. 2017;95:314–8.
Itoh T, Saito M, Marugami N, et al. Correlation between the ABC classification and radiological findings for assessing gastric cancer risk. Jpn J Radiol. 2015;33:636–44.
Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8:8–14.
Samloff IM. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83:204–9.
Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 1987;22(2):133–41.
Naito Y, Ito M, Watanabe T, Suzuki H. Biomarkers in patients with gastric inflammation: a systematic review. Digestion. 2005;72(2-3):164–80.
Yasunaga Y, Bonilla-Palacios JJ, Shinomura Y, et al. High prevalence of serum immunoglobulin G antibody to Helicobacter pylori and raised serum gastrin and pepsinogen levels in enlarged fold gastritis. Can J Gastroenterol. 1997;11:433–6.
Haruma K, Yoshihara M, Sumii K, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28:633–7.
Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol. 1994;89:1211–8.
Inoue M, Kobayashi S, Matsuura A, et al. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomark Prev. 1998;7:261–3.
Kiyohira K, Yoshihara M, Ito M, et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol. 2003;38:332–8.
Yoshihara M, Sumii K, Haruma K, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol. 1998;93:1090–6.
Ito M, Yoshihara M, Takata S, et al. Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese. J Gastroenterol Hepatol. 2012;27:598–602.
Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther. 1999;13:155–62.
Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449–56.
Ohkusa T, Takashimizu I, Fujiki K, et al. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol. 1995;25:317–22.
Hunter FM, Correa P, Fontham E, et al. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci. 1993;38:2081–6.
Takata S, Ito M, Yoshihara M, et al. Host factors contributing to the discovery of gastric cancer after successful eradication therapy of Helicobacter pylori: preliminary report. J Gastroenterol Hepatol. 2007;22(4):571–6.
Haneda M, Kato M, Ishigaki S, et al. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2013;28:78–83.
Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53.
Kitamura Y, Yoshihara M, Ito M, et al. Diagnosis of Helicobacter pylori-induced gastritis by serum pepsinogen levels. J Gastroenterol Hepatol. 2015;30:1473–7.
Kikuchi S, Kato M, Mabe K, et al. Optimal criteria and diagnostic ability of serum pepsinogen values for Helicobacter pylori infection. J Epidemiol. 2018. (in press).
Kiso M, Ito M, Boda T, et al. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor—a multicenter study. Scand J Gastroenterol. 2017;52:828–32.
Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405–14.
Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers. 2010;25:207–12.
Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in eastern Asians: a systematic review and meta-analysis. PLoS One. 2014;9(10):e109783.
Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer. 2008;123:917–26.
Boda T, Ito M, Yoshihara M, et al. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter. 2014;19:1–8.
Kato M, Sasajima M, Ito M, et al. My opinion. Jpn J Helicobacter Res. 2017;18:64–71.
The Japanese Society for Helicobacter Research homepage: http://www.jshr.jp/member/index.html#news170731 (permitted by JSHP).
Kawai T, Ito M, Aoyama N, et al. Evaluation of gastric cancer risk by optimized serum antibody titers against H. pylori: a multi-center retrospective study. Jpn J Helicobacter Res. 2018;19(2),133–8 (in Japanese).
Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.
Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132:1272–6.
Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49:1–8.
Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15:885–91.
Haruma K, Komoto K, Kawaguchi H, et al. Pernicious anemia and Helicobacter pylori infection in Japan: evaluation in a country with a high prevalence of infection. Am J Gastroenterol. 1995;90:1107–10.
Haruma K, Kawaguchi H, Yoshihara M, et al. Relationship between Helicobacter pylori infection and gastric acid secretion in young healthy subjects. J Clin Gastroenterol. 1994;19:20–2.
Miki K, Fujishiro M. Cautious comparison between East and West is necessary in terms of the serum pepsinogen test. Dig Endosc. 2009;21:134–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ito, M. et al. (2019). Serum Markers. In: Shiotani, A. (eds) Gastric Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-13-1120-8_6
Download citation
DOI: https://doi.org/10.1007/978-981-13-1120-8_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1119-2
Online ISBN: 978-981-13-1120-8
eBook Packages: MedicineMedicine (R0)